NCT06575881Recruiting
Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias. The investigators aim to study: 1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy. Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 26 Aug 2024
- Start date
- 13 Dec 2023
- Primary completion date
- Dec 2028
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- Atrial fibrillation
- NCT number
- NCT06575881
What you commit to
- Study type: Observational
- Planned participants: 200
- From 13 Dec 2023 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure
- Previous PVC or VT ablation
- Prior myocardial infarction
Lab values
- LVEF \<20%
Other
- VUS in 'possibly pathogenic' subgroup (control group only)
- Prosthetic mitral or aortic valve
- Contraindication to heparin
Who the study is looking for
- Adults aged 18 and older
- Diagnosed with AF, frequent PVCs, or VT before age 60
- Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation
- Able to provide written, informed consent
- P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.